Elesclomol
In clinical developmentAlso known as 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide, Élesclomol, Elesclomolum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes2
Journals, researchers & institutions
- Journal of experimental & clinical cancer research : CR1
- Ding Y1
- Liu B1
- Lu L1
- Zheng P1
- Zhou C1
- Department of Clinical Medicine1
- Institute of Translational Medicine1
- Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across the same disease area as Elesclomol in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials